Latest Analyst Ratings For Diplomat Pharmacy, Inc. (NYSE:DPLO) – Share Trading News

This post was originally published on this site

Recently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Diplomat Pharmacy, Inc. (NYSE:DPLO).

Recent analyst ratings and price targets:

05/11/2016 – Diplomat Pharmacy, Inc. had its “neutral” rating reiterated by analysts at Mizuho. They now have a USD 33 price target on the stock.

05/10/2016 – Diplomat Pharmacy, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 36 price target on the stock.

04/18/2016 – Avondale Partners began new coverage on Diplomat Pharmacy, Inc. giving the company a “market outperform” rating. They now have a USD 38 price target on the stock.

03/16/2016 – Credit Suisse began new coverage on Diplomat Pharmacy, Inc. giving the company a “neutral” rating. They now have a USD 29 price target on the stock.

03/01/2016 – Diplomat Pharmacy, Inc. was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 30 price target on the stock.

01/06/2016 – Barclays began new coverage on Diplomat Pharmacy, Inc. giving the company a “overweight” rating. They now have a USD 41 price target on the stock.

11/04/2015 – Diplomat Pharmacy, Inc. had its “outperform” rating reiterated by analysts at Raymond James. They now have a USD 45 price target on the stock.

10/21/2015 – UBS began new coverage on Diplomat Pharmacy, Inc. giving the company a “buy” rating. They now have a USD 35 price target on the stock.

10/14/2015 – Diplomat Pharmacy, Inc. was upgraded to “neutral” by analysts at Bank of America Merrill Lynch. They now have a USD 32 price target on the stock.

10/02/2015 – Diplomat Pharmacy, Inc. was downgraded to “equal-weight” by analysts at Morgan Stanley. They now have a USD 31 price target on the stock.

09/23/2015 – Diplomat Pharmacy, Inc. had its “outperform” rating reiterated by analysts at William Blair.

06/22/2015 – Diplomat Pharmacy, Inc. had its “outperform” rating reiterated by analysts at Robert W. Baird. They now have a USD 50 price target on the stock.

05/09/2015 – Diplomat Pharmacy, Inc. was upgraded to “hold” by analysts at Zacks.

Diplomat Pharmacy, Inc. has a 50 day moving average of 29.69 and a 200 day moving average of 30.81. The stock’s market capitalization is 1.88B, it has a 52-week low of 22.41 and a 52-week high of 52.33.

The share price of the company (NYSE:DPLO) was down -3.51%, with a high of 30.26 during the day and the volume of Diplomat Pharmacy, Inc. shares traded was 419407.

Diplomat Pharmacy, Inc. operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. The Company operates through specialty pharmacy services segment. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. Its specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS).

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.